ABBISKO CAYMAN DL-00001 Asset Resilience Ratio
ABBISKO CAYMAN DL-00001 asset resilience ratio. ABBISKO CAYMAN DL-00001 (8ZD) has an Asset Resilience Ratio of 57.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 8ZD days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ABBISKO CAYMAN DL-00001 (2022–2025)
Asset resilience ratio of ABBISKO CAYMAN DL-00001 from 2022 to 2025. This chart shows how ABBISKO CAYMAN DL-00001's Asset Resilience Ratio has changed over time. Read 8ZD total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ABBISKO CAYMAN DL-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABBISKO CAYMAN DL-00001 assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.35 Billion | 57.39% |
| Total Liquid Assets | €1.35 Billion | 57.39% |
Asset Resilience Insights
- Very High Liquidity: ABBISKO CAYMAN DL-00001 maintains exceptional liquid asset reserves at 57.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABBISKO CAYMAN DL-00001 Industry Peers by Asset Resilience Ratio
Compare ABBISKO CAYMAN DL-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
ABBISKO CAYMAN DL-00001 Asset Resilience Ratio by Year (2022–2025)
ABBISKO CAYMAN DL-00001 asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for ABBISKO CAYMAN DL-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.39% | €1.35 Billion ≈ $1.58 Billion |
€2.35 Billion ≈ $2.75 Billion |
-21.86pp |
| 2024-12-31 | 79.25% | €1.67 Billion ≈ $1.95 Billion |
€2.11 Billion ≈ $2.46 Billion |
+13.69pp |
| 2023-12-31 | 65.56% | €1.39 Billion ≈ $1.62 Billion |
€2.12 Billion ≈ $2.47 Billion |
-3.16pp |
| 2022-12-31 | 68.72% | €1.71 Billion ≈ $2.00 Billion |
€2.49 Billion ≈ $2.91 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more